checkAd
    Startseite > Aktien > Xilio Therapeutics > Nachrichten
    Xilio Therapeutics Aktie
    1,1600
     
    USD
    -9,38 %
    -0,1200 USD
    Letzter Kurs 02:00:00 NYSE
    1,1200
     
    USD
    100 STK
    Geldkurs 10.05.24
    1,2200
     
    USD
    100 STK
    Briefkurs 10.05.24
    ISIN: US98422T1007 · WKN: A3C53B · SYM: XLO · USA

    Neueste Nachrichten

    Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
    01.04.24 · globenewswire · Xilio Therapeutics
    Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
    28.03.24 · globenewswire · Xilio Therapeutics
    Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
    28.03.24 · globenewswire · Xilio Therapeutics
    Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
    28.03.24 · Business Wire (engl.) · Gilead Sciences
    Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
    28.02.24 · globenewswire · Xilio Therapeutics
    Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
    31.01.24 · globenewswire · Xilio Therapeutics
    Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
    08.01.24 · globenewswire · Xilio Therapeutics
    Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
    09.11.23 · globenewswire · Xilio Therapeutics
    Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
    03.11.23 · globenewswire · Xilio Therapeutics
    Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting
    31.10.23 · globenewswire · Xilio Therapeutics
    Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
    27.09.23 · globenewswire · Xilio Therapeutics
    Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
    05.09.23 · globenewswire · Xilio Therapeutics